Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PLSE 
Pulse Biosciences Inc (PLSE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: PLSE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 5.93% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) - | Beta 1.63 | 52 Weeks Range 10.52 - 25.00 | Updated Date 06/29/2025 |
52 Weeks Range 10.52 - 25.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.99 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.61% | Return on Equity (TTM) -77.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 903787838 | Price to Sales(TTM) 60.23 |
Enterprise Value 903787838 | Price to Sales(TTM) 60.23 | ||
Enterprise Value to Revenue 64.63 | Enterprise Value to EBITDA -1.81 | Shares Outstanding 67273904 | Shares Floating 17434021 |
Shares Outstanding 67273904 | Shares Floating 17434021 | ||
Percent Insiders 74 | Percent Institutions 8.64 |
Upturn AI SWOT
Pulse Biosciences Inc
Company Overview
History and Background
Pulse Biosciences, Inc. (PLSE) was founded in 2005. It is a commercial-stage medical technology company focused on developing and commercializing its proprietary Nano-Pulse Stimulation (NPS) technology. The company went public in 2015. Initially focused on cosmetic dermatology, the company has expanded to explore applications in cancer therapy and veterinary medicine.
Core Business Areas
- Human Health: Focused on using NPS technology for dermatological procedures, surgical applications, and cancer therapy. Developing systems to clear unwanted skin lesions.
- Veterinary Medicine: Developing and commercializing NPS technology for the treatment of tumors in companion animals.
Leadership and Structure
Kevin Danahy is the CEO. The company has a board of directors overseeing its strategic direction. Pulse Biosciences employs a functional organizational structure with departments focusing on R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- CellFX System: A platform utilizing NPS technology for dermatologic applications, specifically for the treatment of benign lesions. Market share data not publicly available. Key competitors include companies offering laser-based and cryotherapy solutions for skin lesion removal, such as Cynosure (CYNO) before being bought out, Cutera (CTRA), and Alma Lasers.
- DynaPulse NPS System: Veterinary system for treatment of tumors in animals. Market share data not publicly available due to the emerging nature of NPS tech for animal health. Key competitors includes traditional surgery, radiation therapy and chemotherapy providers to address the animal tumor market.
Market Dynamics
Industry Overview
The medical technology industry is highly competitive and constantly evolving, with a focus on innovative solutions for various medical conditions. The dermatological and veterinary markets are growing, driven by increasing awareness of aesthetic procedures and advances in animal healthcare.
Positioning
Pulse Biosciences aims to establish itself as a leader in NPS technology for medical and aesthetic applications, offering a non-thermal alternative to existing treatment modalities. The proprietary NPS technology is the competitive advantage.
Total Addressable Market (TAM)
The TAM for dermatological and veterinary applications is substantial, potentially reaching billions of dollars. Pulse Biosciences is positioned to capture a portion of this market by offering a novel and potentially more effective treatment option, but faces significant competition. Estimating the exact TAM is difficult due to the nascent stage of NPS commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary Nano-Pulse Stimulation (NPS) technology
- Non-thermal treatment modality
- Potential for broad applications across multiple medical fields
- Initial commercialization of CellFX system in dermatology
Weaknesses
- Limited commercial traction to date
- Significant operating losses and cash burn
- Dependence on regulatory approvals
- Limited historical market data
Opportunities
- Expansion of CellFX system applications
- Development of new NPS-based therapies for cancer and other diseases
- Partnerships with leading healthcare providers
- Penetration into the veterinary medicine market
Threats
- Competition from established medical device companies
- Reimbursement challenges from healthcare providers
- Potential for technological obsolescence
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- CTRA
- ALMA (Sisram Medical)
- LMT (as of their acquisition of Coherent)
Competitive Landscape
Pulse Biosciences competes with larger, more established medical device companies. Its competitive advantage lies in its proprietary NPS technology, but it faces challenges in terms of market access and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited, with revenue growth dependent on the commercial success of the CellFX system.
Future Projections: Future growth depends on the company's ability to expand the applications of its NPS technology and secure regulatory approvals. Analyst estimates vary widely. Analyst information can be found on Yahoo Finance.
Recent Initiatives: Focus on expanding the commercial reach of the CellFX system, initiating clinical trials for new NPS-based therapies, and pursuing strategic partnerships.
Summary
Pulse Biosciences is a high-risk, high-reward medical technology company with a proprietary NPS technology. Its strengths lie in its innovative technology and potential for broad applications, but it faces challenges in terms of commercialization, competition, and financial stability. The future success depends on expanding CellFX usage and gaining regulatory approvals. Pulse Biosciences needs to reduce its cash burn rate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Pulse Biosciences SEC Filings
- Company Investor Relations
- Industry Reports (Frost & Sullivan, etc.)
- Analyst Reports (Yahoo Finance)
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pulse Biosciences Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2016-05-18 | President, CEO, Principal Executive Officer, Principal Financial Officer & Co-Chairman of the Board Mr. Paul Arthur LaViolette | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 75 | Website https://www.pulsebiosciences.com |
Full time employees 75 | Website https://www.pulsebiosciences.com | ||
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.